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Summary. Background: Post-thrombotic syndrome (PTS) is a
chronic complication of deep venous thrombosis (DVT).
Objectives: To determine the risk of PTS after DVT and to
assess risk factors for PTS. Methods: Patients were recruited
from the Multiple Environmental and Genetic Assessment
(MEGA) study of risk factors for venous thrombosis. Consec-
utive patients who suffered a first DVT of the leg were included
in a follow-up study.All patients completed aquestionnaire and
DNA was obtained. PTS was ascertained in a structured
interviewusing a clinical classification score.Results:The 1-year
cumulative incidence of PTS was 25% and 7% for severe PTS.
Elastic compression stockings were prescribed in 1412 (85%)
patients. The majority used their stockings every day. Women
were at an increased risk compared with men [risk ratio (RR)
1.5, 95% confidence interval (CI) 1.3–1.8]. Similarly, obese
patients had a 1.5-fold increased risk of PTS compared with
normal weight patients (RR 1.5, 95%CI 1.2–1.9), with a 1-year
cumulative incidenceof 34%comparedwith 22%.Patientswho
already had varicose veins had an increased risk (RR 1.5, 95%
CI 1.2–1.8) of PTS. DVT in the femoral and iliac vein was
associated with a 1.3-fold increased risk of PTS compared with
popliteal vein thrombosis (RR 1.3, 95% CI 1.1–1.6). Patients
over 60 years were less likely to develop PTS than patients
below the age of 30 (RR 0.6, 95% CI 0.4–0.9). Malignancy,
surgery, minor injury, plaster cast, pregnancy or hormone use
did not influence the risk of PTS neither did factor (F)V Leiden
nor the prothrombin 20210A mutation. Conclusions: PTS is a
frequent complication of DVT, despite the widespread use of
elastic compression stockings. Women, obese patients, patients
with proximal DVT and those with varicose veins have an
increased risk of PTS, whereas the elderly appeared to have a
decreased risk.
Keywords: deep venous thrombosis, post-thrombotic syn-
drome, risk factors.
Introduction
Post-thrombotic syndrome (PTS) is a chronic complication of
deep venous thrombosis (DVT). Venous hypertension caused
by venous valvular incompetence and persistent obstruction
are likely to be the pathogenic mechanism underlying PTS [1–
4]. PTS is characterized by symptoms such as a feeling of
heaviness and pain and by signs such as edema, hyperpigmen-
tation and new venous ectasia. Severe PTS can lead to leg
ulcers. Several studies assessed the incidence of PTS which
varied from 15 to 50% between studies [3–10]. This wide range
is as a result of differences in the definition of PTS, patient
selection and study design. There is no gold standard test for
the diagnosis of PTS and the diagnosis is primarily based on
clinical features. Elastic compression stockings assist the calf
muscle pump and reduce venous hypertension and reflux,
thereby reducing edema and improving tissue microcirculation
[1]. Randomized controlled trials have shown that daily use of
elastic compression stockings after DVT reduces the risk of
PTS by approximately 50% [6,8,11].
In contrast to the many identified risk factors for DVT [12],
the only identified risk factors for PTS so far are recurrent,
ipsilateral DVT and an increased body mass index (BMI)
[7,8,13–18]. Age, gender and duration of anticoagulant therapy
did not appear to be associatedwith the risk of developing PTS,
but results are conflicting, and most studies are characterized
by small numbers of patients [8,14–18].
Hypercoagulable states have been reported to be associated
with venous leg ulcers [19–21]. However, factor (F)V Leiden or
the prothrombin 20210Amutation were not associated with an
increased risk of developing PTS [8,14,18,21]. One study even
showed a reduced risk of PTS with the presence of FV Leiden
or the prothrombin 20210 mutation [17]. Other venous
thrombotic risk factors such as surgery and hormone use have
not yet been investigated as potential risk factors for PTS. The
objectives of the present large study were to assess the
cumulative incidence of PTS after a first DVT and to assess
the contribution of risk factors in the development of PTS.
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Methods
Study design
This study was performed in the Multiple Environmental and
Genetic Assessment (MEGA) study of risk factors for venous
thrombosis, a large population-based case–control study.
BetweenMarch 1999 and June 2002, consecutive patients aged
between 18 and 70 years with a first episode of DVT of the leg
were included from six participating anticoagulation clinics in
the Netherlands. Discharge letters and radiology reports of the
venous thrombotic event were obtained. Diagnosis of clinically
suspected DVT of the leg was objectively confirmed by
compression ultrasonography (71%), color-flow Doppler
ultrasound (27%) or by other diagnostic methods [contrast
venography, impedance plethysmography or computed tomog-
raphy of the abdomen (2%)] [22].
Patients who were unable to fill in a questionnaire (see
below) because of language or severe psychiatric problems were
excluded. Among the 2730 eligible patients, 132 died before
they could participate, 31 patients were in the end stage of a
disease, 227 patients could not be located and 424 refused to
participate, resulting into 1916 participating patients in the
MEGA case–control study. In April 2000, three questions
regarding PTS were added to the interview (see below) and 157
patients, who were interviewed before this date, and 13 patients
with missing items regarding PTS in the interview, were
excluded. No information on the left or right side of DVT was
available for 78 patients which led to 1668 patients being
included in the present analysis. These 1668 patients filled in a
questionnaire and participated in an interview. All patients
filled in a detailed questionnaire on acquired risk factors for
venous thrombosis such as malignancy, surgery, minor injury,
plaster cast, bedridden, pregnancy and use of female hormones.
The questionnaire was sent within a few weeks after the event
and covered the period of 1 year prior to the date of the
thrombotic event. When the patient was unable to fill in the
questionnaire, questions were asked by phone, using a
standardized mini-questionnaire. Patients were divided into
groups with idiopathic deep venous thrombosis and provoked
venous thrombosis associated with one or more of the
following risk factors; malignancy, surgery, plaster cast, minor
injury, bedridden at home or in the hospital, pregnancy and the
use of female hormones. Surgery, plaster cast, minor injury and
bedridden at home or in the hospital were considered as a risk
factor when present in the 3 months prior to the thrombosis.
Pregnancy was a risk factor when awomanwas pregnant at the
time of thrombosis or when she gave birth within 3 months
prior to the thrombotic event. Female hormones used at the
time of the thrombosis were considered as risk factors.
BMI was calculated from self-reported weight and height
(weight/height2). BMI was categorized according to the criteria
of the World Health Organization (2000) (World Health
Organisation. Obesity: Preventing and Managing the Global
Epidemic. WHO Obesity Technical Report 2000; Series 894.
World Health Organisation, Geneva, Switzerland), defining
BMI in adults under 18.5 kg m)2 as underweight, a BMI
between 18.5 and 25 kg m)2 as normal, a BMI of 25–
30 kg m)2 as overweight and a BMI ‡ 30 kg m)2 as obesity.
Three months after the patients had discontinued their oral
anticoagulant therapy, they were invited to the anticoagulation
clinic. An independent research assistant, whowas not involved
in their treatment, interviewed the patients and took a blood
sample. In those patients who continued to take oral antico-
agulant therapy for more than 1 year after the event, blood
samples were drawn during therapy and an interview took
place at the same time. If patients were unable to come to the
anticoagulation clinic, an interview was conducted by tele-
phone and buccal swabs were sent by mail to replace the blood
sample [229 out of 1668 patients (13.7%)].
During the in-person or telephone interview, details on
frequency and duration of the use of elastic compression
stockings were asked. PTS was assessed by asking for five
symptoms and four signs (Table 1). These items were based on
the Villalta scale and modified in order to be used in the
interview [7]. Each item scored one point if present. The nine
items were summed into a post-thrombotic score. PTS was
considered absent with a post-thrombotic score between 0 and
3 points. PTS was considered moderate in patients with a score
between 4 and 6 points and severe with a score equal to or
greater than seven or the presence of a venous ulcer. Only the
symptoms and signs of the leg in which the DVT occurred,
were used to assess the presence and severity of PTS. The post-
thrombotic score showed an excellent relation to the Villalta
scale with a kappa of 0.88 (95%Confidence interval 0.79–0.96).
The study protocol was approved by the Ethics Committee of
the Leiden University Medical Center, Leiden, The Nether-
lands. Written informed consent was obtained from all
participants [22].
Laboratory measurements
Blood was collected from the antecubital vein into vacuum
tubes containing 0.106 mol L)1 trisodium citrate. High molec-
ular weight DNA was isolated from leukocytes using a
standard salting-out procedure and stored at )20 C until
amplification. When a blood sample was unavailable, three
large cotton (buccal) swabs in a total of 6 ml SDS-proteinaseK
solution were obtained. DNA was extracted from these buccal
swabs and frozen at )20 C until further analysis [22]. FV
Leiden (G1691A) and the prothrombin (G20210A) mutation
were simultaneously detected by duplex polymerase chain
reaction (PCR) [23,24].
Statistical analyses
The follow-up started at diagnosis of DVT in the leg and ended
at the time of the interview. Cumulative incidence was
estimated using the Kaplan–Meier life table technique. The
reported risk ratios are based on the method of Zhang [25]. In
short, crude odds ratios were used to estimate the relative risk
of PTS. Logistic regression was used to adjust for age and
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gender only, and for age and gender combined with BMI,
duration of symptoms, varicose veins, localization of DVT,
malignancy and elastic compression stockings. Ninety-five
percent confidence intervals (CI) were calculated using the
standard error obtained from the logistic regression model. As
PTS is common (over 10% incidence), the odds ratio (OR)
overestimates the true relative risk (RR). Therefore, the odds
ratio and 95% CI were converted to the risk ratio by taking
into account the prevalence of the risk factor in non-exposed
individuals [25].
As patients had various durations of follow-up and
anticoagulation use, all analyses were stratified by follow-
up and period of anticoagulation use. The Mantel–Haenszel
common OR was used to estimate the relative risk of PTS,
taking these various durations into account. As these
stratified ORs did not differ from the crude analyses, the
risk ratios presented are adjusted for age and gender and
other risk factors as indicated above. All computations were
performed with the use of SPSS software, version 14.0 (SPSS
Inc., Chicago, IL, USA).
Results
Patient characteristics of the 1668 patients are summarized in
Table 2. There were 880 (53%) women, mean age at diagnosis
of DVT was 48 years and patients had a mean BMI of
27 kg m)2. Median duration of symptoms before diagnosis of
DVT was 4 days (5th–95th percentile 0–69). Thrombosis was
unilateral on the left side in 972 (58%) patients, on the right
side in 683 (41%) and bilateral in 13 (1%) patients. DVT was
idiopathic in 24% of all patients. Median duration of
anticoagulation use was 6 months (5th–95th percentile 2–14).
Median duration of follow-up was 10 months (5th–95th
percentile 6–18).
Cumulative incidence and severity of post-thrombotic
syndrome
The 1-year cumulative incidence of PTS was 25%, with a
cumulative incidence of 7% for severe PTS. Table 1 shows the
frequency of the nine post-thrombotic symptoms and signs.
The most frequent symptom reported by 620 (37%) patients
was a feeling of heaviness of the leg. Swelling of the foot or calf
was present in 576 (35%) of the patients. An ulcer was present
in 48 out of 1668 (3%) patients. All patients categorized as
having severe post-thrombotic syndrome had heaviness and
pain of the leg. These symptoms were combined with swelling
and skin changes most of the time (93%) and with newly
formed varicose veins or venous ulcers in 41% of the patients.
Only 466 out of 1668 patients (28%) had a post-thrombotic
score of zero points.
Risk factors for post-thrombotic syndrome
The 1-year cumulative incidence of PTS in women was 31%
compared with 17% in men. Women had a 1.5-fold higher risk
of developing PTS than men (RR 1.5, 95% CI 1.3–1.8), also
after adjustment for other risk factors (RRadjusted 1.5, 95% CI
1.1–1.9) (Table 3). In patients over 60 years, the 1-year
cumulative incidence was 16%, which was much lower than
the 26% cumulative incidence in patients below the age of
30 years (RR 0.6, 95% CI 0.4–0.9). In obese patients, the
Table 1 Post-thrombotic symptoms and signs in 1668 patients
Symptoms n (%) Signs n (%)
Spontaneous pain in calf 433 (26) Newly formed varicose veins 218 (13)
Spontaneous pain on walking 243 (15) Swelling of foot or calf 576 (35)
Spontaneous pain on standing 293 (18) Skin changes, pigmentation, discoloration 418 (25)
Pain worsening during the day 393 (24) Skin changes with venous ulcer 48 (3)
Heaviness of leg 620 (37)
Table 2 Characteristics of 1668 patients with a first deep venous
thrombosis of the leg
Characteristic
Women no (%) 880 (53)
Age (years), mean (SD) 48 (13)
5th–95th percentile 26–67
BMI (kg m)2), mean (SD)* 27 (5)
5th–95th percentile 21–36
Duration of symptoms before
diagnosis (days), median*
4
5th–95th percentile 0–69
Varicose veins at diagnosis 470 (28%)
Side of DVT (%)
Left 972 (58)
Right 683 (41)
Bilateral 13 (1)
Localization of DVT (%)
Calf vein 203 (17)
Popliteal vein 498 (41)
Femoral and iliac vein 502 (42)
Malignancy* 137 (8%)
Surgery within 3 months* 357 (21%)
Minor Injury within 3 months* 405 (24%)
Plaster cast within 3 months 105 (6%)
Pregnancy among women <50 years* 73 (13%)
Oral anticonceptive use among women <50 years 417 (74%)
Hormonal replacement therapy
among women ‡50 years*
39 (13%)
Idiopathic DVT* 389 (24%)
Factor V Leiden mutation* 315 (19%)
Prothrombin 20210A mutation* 92 (6%)
SD, standard deviation; BMI, body mass index; DVT, deep venous
thrombosis.*Unknown in £74 patients. Unknown in 213 patients.
Unknown in 465 patients.
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1-year cumulative incidence was 34%, compared with 22% in
normal weight patients, leading to a 1.5-fold increased risk of
PTS (RR1.5, 95%CI 1.2–1.9). Height of patients did not affect
the risk of PTS. Patients with more than 2 weeks of symptoms
before the DVT had a 1.4-fold increased risk compared with
patient with symptoms for less than 2 weeks (RR 1.4, 95% CI
1.2–1.7). After adjustment for other risk factors for PTS this
effect was no longer present (RRadjusted 1.2, 95% CI 0.9–1.6).
Varicose veins were present in 470 out of 1455 (28%) patients
prior to the DVT, in whom the 1-year cumulative incidence of
PTS was 30%. These patients had a 1.5-fold increased risk of
PTS compared with patients without varicose veins (RR 1.5,
95% CI 1.2–1.8). Newly formed varicose veins is one of the
items of the post-thrombotic score. When this specific item was
excluded from the post-thrombotic score, the risk ratio for
varicose veins was only slightly lower (RR 1.4, 95% CI 1.1–
1.7). Proximal localization of thrombosis in the femoral and
iliac vein was associated with a 1.3-fold increased risk of PTS
comparedwith popliteal vein thrombosis (RR 1.3, 95%CI 1.1–
1.6). Calf vein thrombosis conferred a similar risk for PTS as
popliteal vein thrombosis. Patients with malignancy were less
likely to develop PTS than patients without a malignancy
(RR 0.7, 95% CI 0.4–1.0), which was less pronounced after
adjustment for other risk factors (RRadjusted 0.8, 95% CI
0.4–1.4).
Surgery, minor injury or plaster cast were not associated
with the development of PTS, nor were pregnancy or the use of
female hormones. Patients with an idiopathic DVT conferred a
similar risk for PTS compared with patients with a provoked
DVT (RR 0.9, 95%CI 0.7–1.2). The presence of FV Leiden or
the prothrombin 20210Amutation was not associated with the
development of PTS (Table 4).
Elastic compression stockings
Elastic compression stockings were prescribed in 1412 (85%)
patients. Themajority (77%) of these patients reportedwearing
their stockings every day, 300 (21%) patients did not wear them
daily and only 30 (2%) never used their elastic compression
stockings. Most patients (81%) started to wear elastic
compression stockings within 2 months after the DVT.
Discussion
Twenty-five percent of all patients with a first DVT in the leg
developed PTS within a year, even although a large majority
of the patients reported wearing elastic stockings. Women,
obese patients, patients with proximal DVT and those with
varicose veins had an increased risk of PTS, whereas elderly
patients appeared to have a decreased risk. FV Leiden and
Table 3 Risk factors associated with post-thrombotic syndrome
n PTS, n
One-year cumulative
incidence (%) Risk ratio* Risk ratioadjusted

Gender
Women 880 235 31 1.5 (1.3–1.8) 1.5 (1.1–1.9)
Men 788 129 17 1 1
Age (years)
18–29 200 51 25 1 1
30–39 311 75 26 1.0 (0.7–1.4) 0.8 (0.5–1.2)
40–49 391 111 30 1.2 (0.9–1.6) 1.1 (0.8–1.6)
50–59 456 87 24 0.9 (0.6–1.2) 0.7 (0.4–1.1)
60–69 310 40 16 0.6 (0.4–0.9) 0.4 (0.2–0.7)
BMI
Underweight 15 4 36 1.3 (0.5–2.7) 1.4 (0.4–3.6)
Normal 549 109 22 1 1
Overweight 702 132 22 1.1 (0.8–1.3) 1.2 (0.9–1.6)
Obese 343 102 34 1.5 (1.2–1.9) 1.9 (1.4–2.4)
Duration symptoms before diagnosis, weeks
‡2 368 105 29 1.4 (1.2–1.7) 1.2 (0.9–1.6)
<2 1240 245 24 1 1
Varicose veins at diagnosis§
Yes 470 130 30 1.5 (1.2–1.8) 1.5 (1.2–1.9)
No 985 180 20 1 1
Localization of DVT–
Calf vein 203 37 25 0.9 (0.6–1.3) 0.9 (0.6–1.3)
Popliteal vein 498 100 23 1 1
Femoral and iliac vein 502 128 26 1.3 (1.1–1.6) 1.4 (1.1–1.8)
Malignancy
Yes 137 19 15 0.7 (0.4–1.0) 0.8 (0.4–1.4)
No 1530 344 25 1 1
BMI, body mass index; DVT, deep venous thrombosis. *Adjusted for age and gender if applicable. Adjusted for age, gender and other risk factors
for PTS if applicable (BMI, duration of symptoms, varicose veins, localization, malignancy, recurrent deep venous thrombosis, elastic compression
stocking). Unknown in £74 patients. §Unknown in 213 patients. –Unknown in 465 patients.
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prothrombin 20210A mutation were not associated with the
risk of PTS.
In our study, the 25% 1-year cumulative incidence of PTS is
comparable with the 27% incidence of PTS after 1 year
reported in patients who used elastic compression stockings [6].
This is the first large follow-up study that assesses acquired
and genetic risk factors for the development of PTS in 1668
patients with a first DVT.Women were at a higher risk of PTS
than men, with a cumulative incidence of 31% vs. 17%. The
influence of gender on the development of PTS showed
contradictory results in previous studies. Only one follow-up
study in 244 patients showed an increased risk for women [16],
whereas another study showed an increased risk for men [18].
However, most studies did not find an association [8,15,17].
These contradictory results may be explained by small study
populations [15,17] and the inclusion of patients with recurrent
thrombosis [8,16–18]. Recurrent DVT is a risk factor for PTS
and might have concealed the impact of gender.
Our finding that obesity was associated with PTS has been
reported before [14–18]. Excess body weight might increase
venous pressure and promote reflux in already compromised
veins. Moreover, a high BMI might be related to a lack of
physical exercise and therefore a poor function of the muscle
pump. Obesity is highly prevalent in the general population,
with a prevalence of 21% in our study population, and
showed an increased risk of PTS, with a cumulative incidence
of 34% after 1 year. It is of interest that a high BMI is a risk
factor for PTS, as obesity is a potentially modifiable risk
factor and thus weight reduction may play a role in the
prevention of PTS.
This study identified the presence of varicose veins before the
development of DVT as a risk factor for PTS. Patients with
varicose veins might have a diminished calf muscle pump
function as a result of pre-existing reflux, leading to higher
walking venous pressure and the development of chronic
venous insufficiency [1]. Our study found that proximal DVT is
a risk factor for PTS [18,26]. This association between
localization of the initial thrombus and PTS was not observed
in all previous studies [7,18]. It is an important finding that calf
vein thrombosis conferred a similar risk for PTS as popliteal
vein thrombosis. This finding stresses the importance of
treatment for symptomatic calf vein thrombosis.
Other studies have reported recurrent venous thrombosis as
a risk factor of PTS [7,8,14,16,18]. Unfortunately, we were
unable to investigate recurrent thrombosis as a risk factor for
PTS.
The reduced PTS risk in older patients is an interesting
finding and in contradiction to the increased risk in elderly
patients reported in some [8,16,18], but not all other studies
[15,17]. We included patients below 70 years, where older
patients were included in other studies, which makes it difficult
to compare the results [8,15–17]. The reduced PTS risk may
reflect differences in thrombus propagation in elderly patients.
Recanalization of the thrombus is a relatively fast process, and
most vein segments are recanalized within 3 months. In older
patients, thrombus evolution is an unstable process with
Table 4 Risk factors not associated with post-thrombotic syndrome
Risk factor n PTS, n One-year cumulative incidence (%) Risk ratio*
Surgery within 3 months
Yes 357 82 22 1.1 (0.9–1.3)
No 1308 281 25 1
Minor injury within 3 months
Yes 405 87 25 1.0 (0.8–1.2)
No 1251 274 25 1
Plaster cast within 3 months
Yes 105 24 28 1.1 (0.7–1.5)
No 1563 340 24 1
Pregnant among women <50 years
Yes 73 23 35 1.1 (0.8–1.6)
No 489 141 32 1
Oral anti-conceptive use among women <50
Yes 417 120 30 1.0 (0.7–1.3)
No 146 44 37 1
HRT among women ‡50 years
Yes 39 9 39 1.0 (0.5–1.8)
No 265 58 27 1
Idiopathic DVT
Yes 389 64 18 0.9 (0.7–1.2)
No 1205 284 27 1
Factor V Leiden mutation
Yes 315 74 30 1.1 (0.9–1.4)
No 1311 284 24 1
Prothrombin 20210A mutation
Yes 92 25 24 1.2 (0.9–1.7)
No 1535 333 25 1
HRT, hormonal replacement therapy; DVT, deep venous thrombosis. *Adjusted for age and gender. Unknown in £74 patients.
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continuing propagation for 2 years [27] and therefore older
people might develop PTS later than younger people.
In our study, neither FV Leiden nor the prothrombin
20210Amutation were associated with the onset of PTS, which
is in contrast to what has been suggested by other investigators
[19–21]. This is an important observation as the role of
inherited thrombophilia with regard to the risk of PTS is not
well established [8,14,17–21]. It was recently shown that FV
Leiden and the prothrombin 20210A mutation do not increase
the risk of a recurrent thrombotic event [28]. These results
suggest that inherited thrombophilic work-up is not likely to
confer clinical benefit to the patient regarding the prediction of
the development of PTS.
This study describes the widespread use of elastic compres-
sion stockings. Wearing elastic compression stockings is a
hassle in daily life for patients. It can be difficult to put them on
and take them off, and they can be uncomfortable. The
appearance of elastic compression stockings is also considered
a reason for non-regular use. Despite these disadvantages the
majority of these patients reported to be compliant and use
their stockings every day. This is in accordance with a survey
that showed that patients with DVT are willing to comply with
elastic compression stocking therapy [29].
The 25% 1-year cumulative incidence of PTS is based on
symptoms and signs reported by patients, this may be
considered as a drawback of this study. However, there is no
gold standard test for the diagnosis of PTS. This diagnosis can
be based on clinical signs and symptoms or on objective
assessment of venous valvular insufficiency and venous hyper-
tension. We used a standardized clinical scale, with signs and
symptoms to define presence and severity PTS, which was
derived from the Villalta scale. Sustained venous hypertension,
the underlying pathogenic mechanism of PTS, can be reliably
measured by invasive ambulatory venous pressure tests. This
technique requires special equipment, is invasive, time-con-
suming and cumbersome. It has been shown that PTS
diagnosed with the Villalta scale is associated with an increased
mean invasive venous ambulatory pressure of over 40 mmHg
[30], suggesting that the use of this scale seems justified.
However, until uniform diagnostic criteria for PTS diagnosis
are defined, this will remain a limitation of all clinical studies.
Furthermore, it is difficult to assess whether the symptoms
and signs were directly as a result of venous valvular
incompetence or venous outflow obstruction related to the
DVT, or to other causes of leg venous hypertension. However,
information obtained about signs and symptoms in the leg
without DVT shows a much lower frequency of between 0.4
and 2% (data not shown) than in the leg with deep venous
thrombosis. This supports the hypothesis that these signs and
symptoms are indeed post-thrombotic and not as a result of
other causes of venous hypertension of the leg.
We assessed the presence and severity of PTS at a median of
10 months after diagnosis of DVT and at only one point in
time. It usually takes 3–6 months after an acute DVT for the
initial pain and swelling to resolve and the diagnosis of PTS
should be deferred until later [9,10,27]. In most cases, PTS will
become apparent within 1 year after the acute DVT, with little
increase in incidence thereafter [9]. Thus, the 25% 1-year
cumulative incidence we found may have been an underesti-
mation.
We conclude that PTS remains a frequent complication in
patients with DVT despite the frequent use of elastic compres-
sion stockings. Female gender, older age, obesity and varicose
veins were all associated with the development of PTS, whereas
genetic risk factors were not.
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